Stem cells injected for lung scarring: early trial begins
Disease control
Not yet recruiting
This early-phase trial will test a stem cell product called REGEND007 in 12 people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. The stem cells are given through an IV, and the main goal is to check safety and find the right do…
Phase: EARLY_PHASE1 • Sponsor: Regend Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC